Trial · NCT02545907
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Dose-Limiting Toxicities as Assessed by Reported Data | After 1 cycle of treatment; to be completed within 1 year. | Evaluable set- patient who received at least one cycle of the study treatment. KTD Patients who do not receive one complete cycle due to experiencing a DLT will be included in the analysis; patients who do not receive at least one complete cycle for reasons other than toxicity, without experiencing a DLT, and who miss a dose of Carfilzomib, more than 14 doses Thalidomide or 2 doses of Dexamethasone in the first cycle, will be replaced. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Participants Experiencing Grade 3 or 4 Toxicity as Assessed by CTCAE v4.0. | Between informed consent provided and 30 days post last trial treatment administration, up to 7 months | All patients that receive at least one dose of Carfilzomib and with no protocol deviations with relevant impact on safety will be included in the safety analysis set. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Clonal Response Rate Within 3 Months, at 3 Months, Within 6 Months and at 6 Months as Determined by Paraprotein and Free Light Chain Assessment. | Within 3 months, at 3 months, within 6 months and at 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Amyloidotic Organ Response Rate Within 3 Months and 6 Months Based on Biochemical, Electrocardiographical, and Radiographical Assessment. | Within 3 months and 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Time to Amyloidotic Organ Response Based on Reported Data. | Within 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Deaths at 6 Months Based on Reported Data. | 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Patients Progression-free at 6 Months Based on Reported Data. | 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Maximum Response Determined by Paraprotein and Free Light Chain Assessment. | Within 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Time to Maximum Response Based on Reported Data. | Within 6 months | months | MEDIAN | |
| SECONDARY | Number of Patients Withdrawing From Treatment Based on Reported Data. | Within 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Patients Experiencing Dose Delays Based on Reported Data. | Within 6 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Compliance Profile of KTD Based on Reported Chemotherapy Compliance Data. | Within 6 months | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02545907/outcomes